ClinicalTrials.gg
CompletedNCT06396429Updated Jul 11, 2025

To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

A Phase 3 interventional study of HRS9531 injection and HRS9531 injection in Overweight or Obesity, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
567
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing ribupatide in Obesity — 2 open to participants now, 9 under way, 6 of them phase 3. ribupatide · Obesity.

Enrollment
5th of 16
567 · median 142
Started
2024
with 2 others
Phase 3
7 of 16
1 open now
Registered
4th of 16
by date
Lead sponsor
9 of 16
Fujian Shengdi Pharmaceutical Co., Ltd.

Among the 16 studies testing ribupatide in Obesity, this one is the 5th largest by enrollment, is one of 3 that started in 2024, is one of 7 in phase 3, and was the 4th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

2 of the 16 studies testing ribupatide in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ribupatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing ribupatide in Obesity, or all of them as a file.
02

Study summary

The study aims to evaluate the efficacy and safety of HRS9531 in subjects with overweight or obese for 48 weeks.

03

Conditions studied

  • Overweight or Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 567 is above the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Male or female subjects, ≥18 years of age at the time of signing informed consent.
  3. At screening visit, ≥28.0 Kg/m2, or ≥24 Kg/m2 with at least one weight-related complication, such as prediabetes, hypertension, dyslipidemia, obstructive sleep apnea, and nonalcoholic fatty liver disease.
  4. Diet and exercise control for at least 3 months before screening visit, and less than 5 kg self-reported change within the last 3 months.
  5. Fertile male and female subjects (including partners) have no plans to have children and agree to use effective within 2 months after signing the informed consent form and the last medication, and fertile female or male subjects have no plans to donate eggs/sperm; Fertile female subjects tested negative for regnancy within the first 3 days of randomization and were not lactating.

Exclusion criteria

Exclusion Criteria:

  1. Presence of lab results at screening visit;
  2. Uncontrollable hypertension;
  3. PHQ-9 score ≥15;
  4. Medical history or illness that affects your weight;
  5. History of diabetes;
  6. Acute infection, acute trauma, or medium to large surgery within 1 month prior to screening;
  7. History of acute cardiovascular and cerebrovascular diseases within 6 months prior to screening;
  8. Any organ-system developed within 5 years except for cured local basal cell cancer of the skin、 in-situ cancer of the cervix and in-situ cancer of the prostate;
  9. Confirmed or suspected depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illness;
  10. Known or suspected history of alcohol and/or substance abuse or drug abuse;
  11. History of acute or chronic hepatitis or other serious liver disease other than alcoholic fatty liver disease.
  12. Have received or plan to have an organ or bone marrow transplant during the study.
  13. The presence of any blood disorders that may interfere with testing.
  14. disease is present and systemic therapy or therapy is planned during the study.
  15. Use of drugs or treatments that may have caused significant weight gain or loss within the 3 months prior to screening;
  16. Weight loss surgery or endoscopic and/or medical device-based weight loss therapy is planned for or during the study period;
  17. Use of drugs or treatments that may have caused significant weight gain or loss within the 3 months prior to screening;
  18. Patients with blood donation or blood loss ≥400 mL or receiving blood transfusion within 3 months before screening.
  19. Surgery is planned during the tria;
  20. Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process;
  21. In the investigator's judgment, there are circumstances (medical, psychological, social, or geographical factors, etc.) that affect subject safety or any other conditions that interfere with the evaluation of the test results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
567 participants (actual)

Study arms

  • Experimental
    Treatment group A: HRS9531 injection

    Drug: HRS9531 injection

  • Experimental
    Treatment group B: HRS9531 injection

    Drug: HRS9531 injection

  • Experimental
    Treatment group C: HRS9531 injection

    Drug: HRS9531 injection

  • Placebo comparator
    Placebo injection

    Drug: Placebo

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage change from baseline in weight after 48 weeks of treatment

    Time frame: Baseline, Week 48

  2. Proportion of subjects with weight loss of≥5% from baseline after 48 weeks of treatment

    Time frame: Week 48

Secondary outcomes

  1. Proportion of subjects with weight loss of ≥10% from baseline after 48 weeks of treatment

    Time frame: Week 48

  2. Proportion of subjects with weight loss of ≥15% from baseline after 48 weeks of treatment

    Time frame: Week 48

  3. Change from baseline in waist circumference after 48 weeks of treatment

    Time frame: Baseline, Week 48

  4. Change from baseline in weight after 48 weeks of treatment

    Time frame: Baseline, Week 48

  5. Change from baseline in BMI after 48 weeks of treatment

    Time frame: Baseline, Week 48

  6. Change from baseline in systolic blood pressure after 48 weeks of treatment

    Time frame: Baseline, Week 48

  7. Change from baseline in diastolic blood pressure after 48 weeks of treatment

    Time frame: Baseline, Week 48

  8. Change from baseline in Total Cholesterol after 48 weeks of treatment

    Time frame: Baseline, Week 48

  9. Change from baseline in Low Density Lipoprotein (LDL) Cholesterol after 48 weeks of treatment

    Time frame: Baseline, Week 48

  10. Change from baseline in Triglycerides after 48 weeks of treatment

    Time frame: Baseline, Week 48

  11. Change from baseline in High Density Lipoprotein (HDL) Cholesterol after 48 weeks of treatment

    Time frame: Baseline, Week 48

  12. Change from baseline in fasting plasma glucose (FPG) after 48 weeks of treatment

    Time frame: Baseline, Week 48

  13. Change from baseline in glycosylated haemoglobin (HbA1c) after 48 weeks of treatment

    Time frame: Baseline, Week 48

  14. Change from baseline in fasting serum insulin after 48 weeks of treatment

    Time frame: Baseline, Week 48

  15. Change in scores of SF-36 V2 from baseline after 48 weeks of treatment

    Time frame: Baseline, Week 48

  16. Number of AEs during the trial

    Time frame: week 0 to week 52

08

Study locations

1 site
  • Zhongshan Hospital Affiliated to Fudan University
    Shanghai, Shanghai Municipality 200032, China
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Jul 2025, 13 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 13 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 2, 2024
StartActual
May 13, 2024
Primary completionActual
Jul 7, 2025
CompletionActual
Jul 7, 2025
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06396429
Responsible party
Sponsor
First posted
May 2, 2024
Start date
May 13, 2024
Primary completion
Jul 7, 2025
Completion
Jul 7, 2025
Last update
Jul 11, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ribupatide

Start the discussion